linjc16/ctgov huggingface dataset:
The Oakland Men's Health Disparities Study

Study Overview
=================
Brief Summary
-----------------
Reducing racial disparities in health outcomes is a major policy concern in the United States. Although there has been recent progress to close the gap, black men continue to experience earlier morbidity and mortality from preventable and manageable medical conditions, and live on average 4.2 years less than their white male peers. An oft-prescribed solution to close this stubborn gap is to increase the diversity of the healthcare workforce. Another common policy tool to increase take-up of preventative healthcare services is financial incentives. In this randomized evaluation, we will estimate the effects of financial incentives and a racially concordant physician on the uptake of preventive health services in Oakland, California.

Official Title
-----------------
The Oakland Men's Health Disparities Study

Conditions
-----------------
Behavior, Cardiovascular Risk Factor, Influenza

Intervention / Treatment
-----------------
* Behavioral: Concordant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: African American male adults Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: RCT
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Discordant<br>Does not receive the concordant provider. | Behavioral: Concordant<br>* We will be randomizing across providers - we are particularly interested in racial concordance.<br>|
| Experimental: Concordant<br>The intervention is that the subject receives the concordant provider. | Behavioral: Concordant<br>* We will be randomizing across providers - we are particularly interested in racial concordance.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Take-up of Preventive Services (Post-consultation) | Take-up of preventative services was scored as either zero (did not utilize any post-consultation services) or 1 (utilized at least 1 post-consultation service). Four non-incentivized post-consultation preventive services were offered (for BMI, blood pressure, cholesterol, and/or diabetes); the subject had the opportunity to select service(s) after meeting with their assigned doctor. | 1 day |
Epiretinal Proliferation in Eyes With Full Thickness Macular Hole

Study Overview
=================
Brief Summary
-----------------
We evaluated preoperative and postoperative optical coherence tomograpghic images in eyes with full thickness macular hole (FTMH) whether the epiretinal proliferation (EP) was detected and detection of EP was correlated to the visual improvement.

Detailed Description
-----------------
We evaluated preoperative and postoperative optical coherence tomograpghic images in eyes with full thickness macular hole (FTMH) whether the epiretinal proliferation (EP) was detected and detection of EP was correlated to the visual improvement.

Official Title
-----------------
Epiretinal Proliferation in Eyes With Full Thickness Macular Hole

Conditions
-----------------
Macular Disease

Intervention / Treatment
-----------------
* Procedure: Vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eyes with macular hole Exclusion Criteria: Eyes with retinal detachment, retinal vascular disease, glaucoma, proliferative diabetic retinopathy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Eyes with epiretinal proliferation<br>The eyes with epiretinal proliferation around the macular hole detected with optical coherence tomography | Procedure: Vitrectomy<br> <br> |
| Eyes without epiretinal proliferation<br>The eyes without epiretinal proliferation around the macular hole detected with optical coherence tomography | Procedure: Vitrectomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recovery of foveal microstructure |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual improvement |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
idiopathic macular hole
Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
This extension study is to assess the long-term safety of EC-MPS

Official Title
-----------------
A Prospective, Open-label, Multicenter, International Follow-up Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

Conditions
-----------------
Renal Transplantation

Intervention / Treatment
-----------------
* Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion / Exclusion Criteria - All patients who completed study CERL080A2405-IN01 and who are willing to continue treatment with Enteric-Coated Mycophenolate Sodium. Other protocol-defined inclusion / exclusion criteria may apply -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess patient and graft survival, acute rejection incidence, graft function and specific pertinent safety parameters in de novo renal transplant recipients. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the respective influence of parameters (demographic characteristics, transplant-related variables, medical conditions and post-transplantation complications) on clinical outcomes. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EC-MPS, renal transplantation, de novo patients
Smoking Cessation in Menthol Flavored Cigarette Smokers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if in smokers of menthol cigarettes, switching to non-menthol cigarettes prior to a cessation attempt results in greater cessation success than attempting to quit without first switching

Conditions
-----------------
Tobacco Use Disorder

Intervention / Treatment
-----------------
* Other: switch to non-menthol cigarettes prior to cessation attempt
* Other: continue smoking menthol cigarettes prior to cessation attempt


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Self identify as African American smoke primarily menthol cigarettes be between the ages of 18 and 64 smoke a minimum number of cigarettes per day express an interest in quitting smoking Exclusion Criteria: current unstable medical / psychiatric condition regular use any form of nicotine or tobacco other than cigarettes are pregnant or breast feeding The investigators will evaluate if there are other reasons why someone may not be eligible to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Continue smoking menthol cigarettes<br>Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking | Other: continue smoking menthol cigarettes prior to cessation attempt<br> <br> |
| Other: Switch to non-menthol cigarettes<br>Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking | Other: switch to non-menthol cigarettes prior to cessation attempt<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Lapse | Time from smoking cessation until first lapse (i.e. a cigarette is smoked) | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Relapse | Days from the quit attempt until the first of seven consecutive smoking days | 6 months |
Requests for Euthanasia and Assisted Suicide

Study Overview
=================
Brief Summary
-----------------
This study take place in the palliative care units of Burgundy-Franche-Comté regions and at the Maison Médicale Jeanne Garnier. The main aim of this project is to analyze and understand the meaning of explicit requests to hasten death (euthanasia and assisted suicide). This involves conducting interviews with patients, carers to whom the request has been expressed and a relative chosen by the patient. This study aims to describe the request over time. This will be done through two series of interviews, one as soon as it is first expressed, then one week later.

Official Title
-----------------
Requests for Euthanasia and Assisted Suicide: a Prospective, Multicenter and Qualitative Study of Their Frequency and Characteristics, of Patients' Motivations and Their Evolution

Conditions
-----------------
Palliative Care, End of Life, Euthanasia, Assisted Suicide, Qualitative Research

Intervention / Treatment
-----------------
* Other: Qualitative research


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult not under guardianship or curatorship, Hospitalized in palliative care units of Bourgogne-Franche-Comté region and in the Maison Médicale Jeanne Garnier in Paris, At the end of life due to advanced stage disease or a major change in the state of health of an elderly person, They have made an explicit request for euthanasia or assisted suicide, They are in capacity to meet researchers for interview, Having consented to interviews, They are covered by the French social security system. Exclusion Criteria: Adult under guardianship or curatorship, They are underage, They are not hospitalized in Palliative Care Unit of Bourgogne-Franche-Comté region and in the Maison Médicale Jeanne Garnier, The request was expressed by another person or not explicit, They didn't consent to interviews, The request appears in the context of a situation other than illness or a general change in state of health They are not in capacity to meet researchers for interviews.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Qualitative research<br>Semi-structured interviews | Other: Qualitative research<br>* Semi-structured interviews<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 70 semi-structured interviews | Qualitative data analysis - Theoretical concept saturation and thematic analyses. [analyze and understand the meaning of explicit requests to hasten death (euthanasia and assisted suicide)] | 12 months |
Simulated Clinical Use Testing on Safe'N'Sound 1ML Stalked Passive Delivery System With Add-On Extended Finger Flanges

Study Overview
=================
Brief Summary
-----------------
A simulated clinical use testing the Save'N'Sound 1mL staked Passive Delivery System with add-on extended finger flanges

Detailed Description
-----------------
This study aims to evaluate the safety of the use of the Safe'N'Sound 1mL staked passive delivery system cone version with add-on EFF in the prevention of needle stick injuries and to evaluate the user's satisfaction with regards to the handling characteristics of the product namely safety, design and the ease of use.

Official Title
-----------------
Simulated Clinical Use Testing on Safe'n'Sound 1mL Staked Passive Delivery System With add-on Extended Finger Flanges

Conditions
-----------------
Needle Stick

Intervention / Treatment
-----------------
* Device: Safe'N'Sound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The Evaluator must be: Minimum of age 18 Able to understand and provide signed consent for the study Willing to comply with the study protocol, including being willing to answer questions and complete questionnaires Have no concerns about the ability to perform the simulated injections With no financial interest in the sponsor (Nemera) or the CRO (NAMSA) Exclusion Criteria: If in the opinion of CRO, including the observer/monitor, the potential evaluator is not a good candidate for the study, including the reasons such as mental health.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Single Arm<br> | Device: Safe'N'Sound<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The true failure rate of the Safe'n'Sound 1mL Staked Passive Delivery system with add-on extended finger flange |  | At time of testing, day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ease of Use |  | At time of testing, day 1 | 
| Evaluator assessment of device handling |  | At time of testing, day 1 | 
| Evaluator assessment of instructions |  | At time of testing, day 1 | 
| Evaluator assessment of improvement of device over predecessor device |  | At time of testing, day 1 |
CTAG Dissection/Trauma Post Marketing Surveillance Japan

Study Overview
=================
Brief Summary
-----------------
Post Marketing Surveillance of the Conformable GORE® TAG® Thoracic Endoprosthesis

Official Title
-----------------
Post Marketing Surveillance of the Conformable GORE® TAG® Thoracic Endoprosthesis

Conditions
-----------------
Thoracic Aortic Aneurysm, Thoracic Aorta Injury, Thoracic Aortic Dissection

Intervention / Treatment
-----------------
* Device: Conformable GORE® TAG® Thoracic Endoprosthesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for Acute, Complicated Stanford Type B Aortic Dissection: Patient present with acute complicated type B aortic dissection Patient who do not respond to medical therapy Time from symptom onset to dissection diagnosis ≤ 14 days Adequate iliac / femoral access or conduit Aortic inner diameter at proximal extent of proximal landing zone in the range of 16-42 mm ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected Inclusion Criteria for Traumatic Aortic Transection: Patient has traumatic aortic transection that requires repair as determined by treating physician Adequate iliac / femoral access Aortic inner diameter in the range of 16-42 mm on the proximal and distal sides ≥ 20 mm non-aneurysmal aorta neck proximal and distal to the lesion
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Conformable GORE® TAG® Thoracic Endoprosthesis|Thoracic Endoprosthesis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary entry tear exclusion | To evaluate how many subjects achieved the primary entry tear exclusion at 1-month follow up | Within 1-month follow up after the initial procedure (30 days) |
Are Surgeons Ready to Get the COVID-19 Vaccine?

Study Overview
=================
Brief Summary
-----------------
The COVID-19 pandemic continues to rage and most of the world is facing a second wave with continuous lockdown and strict measures aiming to control it. While vaccination is on its way, and has even started in several countries, trust and acceptance remain a challenge for an effective vaccination strategy, especially with the increasing vaccination hesitance in recent years . It is important to understand the main concerns towards the COVID-19 vaccine so they can be addressed in a constructive way - more specifically among health care professionals who are at the frontline of the pandemic. The aim of this study is to evaluate whether surgeons are ready for the COVID-19 vaccine and to understand their main concerns towards the vaccine. In an objective to evaluate the attitude of doctors towards the COVID vaccine and the effect of prolonged lockdown on their psychological burden, the investigators created an anonymous survey of 21 questions.

Official Title
-----------------
Are Surgeons Ready to Get the COVID-19 Vaccine?

Conditions
-----------------
Covid19

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physicians affiliated to Belgian Hospitals Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Doctors within Belgian Hospitals<br> | Other: Survey<br>* Survey of 21 questions. The questions were divided into sections, evaluating demographics, COVID-19 test status and symptoms, the surgeon's opinion on the COVID-19 vaccination and their main concerns. The questionnaire was completed anonymously between 15/01/2021 and 24/01/2021, before the start of vaccination of health care professionals in a Belgian hospital.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perception and knowledge towards the vaccine | Survey (21 items). Qualitative questionnaire about the vaccine. | 15 minutes |
Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators look at the genetic expressional alteration which influenced on the early lateral neck node metastasis in thyroid papillary microcarcinoma.

Detailed Description
-----------------
Papillary thyroid carcinomas (PTCs) measuring 1.0 cm or less in diameter were defined as papillary thyroid microcarcinomas (PTMCs) by the World Health Organization (WHO), emphasizing on their benign behavior, probably of little clinical significance, which do not affect patients' survival. However, some reported that PTMCs may have aggressive behavior, can cause locoregional recurrences, cervical lymph node metastases, and even distant metastases. But till now, the characteristics of PTMCs with early lateral neck node metastasis were only reviewed and described by the clinicopathological parameters, and no analysis of PTMCs by the gene level is available. In these study, we investigate the genetic expressional alteration which influenced on the early lateral neck node metastasis in thyroid papillary microcarcinoma.

Official Title
-----------------
Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis

Conditions
-----------------
Papillary Thyroid Microcarcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age≥20 years old Conventional type papillary thyroid microcarcinoma (0.5cm≤tumor size≤1.0cm) group 1: no lymph node metastasis /group 2: with lateral neck node metastasis Exclusion Criteria: tumor with capsular invasion (T3 tumor) distant metastasis combined underlying thyroiditis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>papillary thyroid microcarcinoma without lymph node metastasis | |
| Group 2<br>papillary thyroid microcarcinoma with lateral lymph node metastasis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mRNA expression pattern by microarray analysis | mRNA expression differences between papillary thyroid microcarcinoma without lateral neck node metastasis and the one with lateral neck node metastasis. (The outcome will be measured within 24-hour after surgical removement using papillary thyroid microcarcinoma tissue.) | 24-hour after surgical removement |